Respiree Care and 1Bio Platform

Respiree is a Singapore medical technology company founded by Dr Gurpreet Singh, a former A*STAR senior research fellow. It builds a cardio-pulmonary monitoring platform that detects patient deterioration early, in hospital wards and in remote care settings.

The RS001 wearable sensor captures lung and heart biomarkers and sends data through cellular hubs to the 1Bio connected care platform, where 1Bio AI-Acute flags acute deterioration. Respiree Care packages this for hospital-at-home, chronic disease management and rehabilitation with EHR integration and configurable alerts, while Respiree 1Bio supports decentralized clinical trials and digital biomarker development. Customers include health systems, medtech and biopharma companies.

• RS001 wearable: captures comprehensive lung and cardio biomarkers.
• 1Bio AI-Acute: AI early warning of acute deterioration, cleared by HSA as Class B SaMD.
• Respiree Care: enterprise remote care for hospital-at-home, chronic disease and rehabilitation.
• EHR integration: secured dashboards connected to enterprise and EHR systems.
• Alerts: customizable feedback and alert rules for care teams.
• Respiree 1Bio: decentralized clinical trials platform with digital biomarker development.

Vietnamese tertiary hospitals could monitor COPD and heart failure patients at home after discharge to reduce readmissions. General wards could use AI early warning to cut routine nurse checks. Pharmaceutical companies running trials in Vietnam could collect respiratory digital biomarkers remotely.

Detects deterioration days in advance with more than 90% accuracy, according to the company. A study with Mayo Clinic reported up to 16-fold better precision than conventional hospital alarms. Could save nurses up to 12 hours a day in a 40-bed ward by reducing routine bedside checks. Helps reduce readmissions and costs through remote alerts.

Aging populations and nurse shortages are pushing hospitals to adopt continuous monitoring and hospital-at-home models. Regulators in Singapore and the US now clear AI early warning software, and large Vietnamese hospitals facing overcrowding are exploring remote monitoring after discharge.

Respiree Pte Ltd is based in Singapore and grew from two people to close to 40. Raised an 11.6 million USD Series A in 2025. Holds US FDA 510(k), CE, TGA and HSA clearances, ISO 13485 and ISO 27001. Partners include Philips, Mayo Clinic Solution Studio and Roche Diagnostics. President's Technology Award 2024.